Introduction: Adolescent HPV vaccination rates remain suboptimal. The purpose of the study was
to investigate attitudes about HPV vaccine relative to other adolescent vaccines among clinical
staff from primary care offices and school based clinics. Methods: We interviewed clinicians in
primary care offices and school-based clinics regarding their attitudes about HPV vaccine relative
to Tdap and MCV4. Results: Respondents (n = 36) included clinical staff in family medicine (47%),
pediatrics (25%), obstetrics/gynecology (19%) and school-based health clinics (8%). Only 3%
strongly agreed and 17% agreed that completion of HPV vaccine was more important than completion
of pertussis vaccine (Tdap), while 6% strongly agreed and 33% agreed that completion of
HPV vaccine was more important than completion of meningitis vaccine (MCV4). Discussion: Providing
clinicians with additional information about the cancer prevention benefits of the HPV vaccine
and the greater risk for HPV infection/disease relative to other vaccine preventable adolescent
diseases may help to increase HPV vaccination rates among adolescents.
References
[1]
Centers for Disease Control and Prevention (2014) Genital HPV-Fact Sheet. http://www.cdc.gov/std/HPV/stdfact-HPV.htm
[2]
Mahoney, M.C. (2006) Protecting Our Patients from HPV and HPV-Related Diseases: The Role of Vaccines. Journal of Family Practice.
[3]
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1995) Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, World Health Organization, International Agency for Research on Cancer, Lyon
[4]
Centers for Disease Control (CDC) (2014) How Many Cancers Are Linked with HPV Each Year? http://www.cdc.gov/cancer/HPV/statistics/cases.htm
[5]
Zandberg, D.P., Bhargava, R., Badin, S. and Cullen, K.J. (2013) The Role of Human Papillomavirus in Nongenital Cancers. CA: A Cancer Journal for Clinicians, 63, 57-81. http://dx.doi.org/10.3322/caac.21167
[6]
Centers for Disease Control and Prevention (CDC) (2011) Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males—Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. doi:mm6050a3 [pii]
[7]
Centers for Disease Control and Prevention (CDC) (2010) FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. doi:mm5920a4 [pii].
[8]
Markowitz, L.E., Dunne, E.F. and Saraiya, M., Centers for Disease Control and Prevention (CDC) (2014) Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 29 August 2014/63 (RR05), 1-30.
[9]
Petrosky, E., Bocchini Jr., J.A., Hariri, S., Chesson, H., Curtis, C.R., Saraiya, M., Unger, E.R. and Markowitz, L.E. (2015) Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 29 March 2014/64, 300-304.
[10]
Centers for Disease Control and Prevention (CDC) (2013) Human Papillomavirus Vaccination Coverage among Adolescent Girls, 2007-2012, and Postlicensure Vaccine Safety Monitoring, 2006-2013—United States. MMWR. Morbidity and Mortality Weekly Report. doi:mm6229a4 [pii]
[11]
Reagan-Steiner, S., Yankey, D., Jeyarajah, D., Elam-Evans, L.D., Singleton, J.A., Curtis, C.R., MacNeil, J., Markowitz, L.E. and Stokley, S. (2015) National, Regional, State, and Selected Local Area Vaccination Coverage among Adolescents Aged 13-17 Years—United States, 2014. Morbidity and Mortality Weekly Report, 31 July 2015/64, 784-792.
[12]
Holman, D.M., Benard, V., Roland, K.B., Watson, M., Liddon, N. and Stokley, S. (2014) Barriers to Human Papillomavirus Vaccination among US Adolescents: A Systematic Review of the Literature. JAMA Pediatrics, 168, 76-82. http://dx.doi.org/10.1001/jamapediatrics.2013.2752
[13]
Gilkey, M.B., Moss, J.L., Coyne-Beasley, T., Hall, M.E., Shah, P.D. and Brewer, N.T. (2015) Physician Communication about Adolescent Vaccination: How Is Human Papillomavirus Vaccine Different? Preventive Medicine, 77, 181-185. http://dx.doi.org/10.1016/j.ypmed.2015.05.024
[14]
Allison, M.A., Hurley, L.P., Markowitz, L., Crane, L.A. Brtnikova, M., Beaty, B.L., Snow, M., Cor, J.Y, Stokley, S., Roark, J. and Kempe, A. (2016) Primary Care Physicians’ Perspectives about HPV Vaccine. Pediatrics. doi:peds.2015-2488 [pii]
[15]
Fisher, H., Trotter, C., Hickman, M. and Audrey, S. (2014) Barriers and Facilitators to HPV Vaccination of Young Women in High-Income Countries: A Qualitative Systematic Review and Evidence Synthesis. BMC Public Health, 14, 1.
[16]
Brewer, N.T., Gottlieb, S.L., Reiter, P.L., McRee, A.L., Liddon, N., Markowitz, L. and Smith, J.S. (2011) Longitudinal Predictors of Human Papillomavirus Vaccine Initiation among Adolescent Girls in a High-Risk Geographic Area. Sexually Transmitted Diseases, 38, 197-204. http://dx.doi.org/10.1097/OLQ.0b013e3181f12dbf
[17]
Perkins, R.B., Clark, J.A., Apte, G., Vercruysse, J.L., Sumner, J.J., Wall-Haas, C.L., Rosenquist, A.W. and Pierre-Joseph, N. (2014) Missed Opportunities for HPV Vaccination in Adolescent Girls: A Qualitative Study. Pediatrics, 134, e666-e674. http://dx.doi.org/10.1542/peds.2014-0442
[18]
McRee, A.-L., Gilkey, M.B. and Dempsey, A.F. (2014) HPV Vaccine Hesitancy: Findings from a Statewide Survey of Health Care Providers. Journal of Pediatric Health Care, 28, 541-549. http://dx.doi.org/10.1016/j.pedhc.2014.05.003
[19]
Reiter, P.L., McRee, A.-L., Pepper, J.K., Gilkey, M.B., Galbraith, K.V. and Brewer, N.T. (2013) Longitudinal Predictors of Human Papillomavirus Vaccination among a National Sample of Adolescent Males. American Journal of Public Health, 103, 1419-1427. http://dx.doi.org/10.2105/AJPH.2012.301189
[20]
de Sanjose, S., Quint, W.G.V., Alemany, L., Geraets, D.T., Klaustermeier, J.E., Lloveras, B., Tous, S., Felix, A., Bravo, L.E. and Shin, H.-R. (2010) Human Papillomavirus Genotype Attribution in Invasive Cervical Cancer: A Retrospective Cross-Sectional Worldwide Study. The Lancet Oncology, 11, 1048-1056. http://dx.doi.org/10.1016/S1470-2045(10)70230-8
[21]
Centers for Disease Control and Prevention (CDC) (2015) 2014 Provisional Pertussis Surveillance Report. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6353md.htm?s_cid=mm6353md_w
[22]
MacNeil, J. and Cohn, A. (2011) Chapter 8: Meningococcal Disease. In: VPD Surveillance Manual, Centers for Disease Control (CDC), Atlanta, 1-11.
[23]
Kahneman, D. and Tversky, A. (1979) Prospect Theory: An Analysis of Decision under Risk. Econometrica, 47, 263-292. http://dx.doi.org/10.2307/1914185
[24]
Brewer, N.T. and Chapman, G.B. (2003) Contrast Effects in Judgments of Health Hazards. The Journal of Social Psychology, 143, 341-354. http://dx.doi.org/10.1080/00224540309598449
[25]
Briss, P.A., Rodewald, L.E., Hinman, A.R., Shefer, A.M., Strikas, R.A., Bernier, R.R., Carande-Kulis, V.G., Yusuf, H.R., Ndiaye, S.M. and Williams, S.M. (2000) Reviews of Evidence Regarding Interventions to Improve Vaccination Coverage in Children, Adolescents, and Adults. American Journal of Preventive Medicine, 18, 97-140. http://dx.doi.org/10.1016/S0749-3797(99)00118-X
[26]
Dempsey, A.F. and Mendez, D. (2010) Examining Future Adolescent Human Papillomavirus Vaccine Uptake, with and without a School Mandate. Journal of Adolescent Health, 47, 242-248.e6. http://dx.doi.org/10.1016/j.jadohealth.2009.12.009
